newsletter masthead
July 25, 2019
DON'T MISS IT: THE ANNUAL SCIENTIFIC RETREAT IS HERE
Today: Case CCC TED Talks
July 25, 5p | Tinkham Veale University Center

All are invited to join us in the ballroom of Tinkham Veale University Center at 5 pm today for TED talks from local prominent researchers, Brian Bolwell, MD, Peter Pronovost, MD, PhD, FCCM, and Mark Griswold, PhD as part of the Case Comprehensive Cancer Center's Annual Scientific Retreat, which begins at 2:30 pm.

These three leaders in their fields provide remarkable insight and passion for breaking ground in new areas, leading by collaboration and always seeking to better mankind.  Click here to read more about each of the presenters.

TED Talk Presentations:
  • "Leadership 101"
  • "From Healing and Hospitals to Healthy at Home"
  • "How Holographic Visualization Will Disrupt Our World"
Thursday's presentations are open to all and the full retreat agenda is available for those members, fellows, post-docs and trainees registered for the two-day event.

Parking
Parking is available in the Campus Center Severance Garage (Lot 29) at  11181 East Blvd,  Cleveland, Ohio 44106. Attendees must pick up a parking voucher at the registration desk.  We look forward to seeing you there!
Friday: Annual Scientific Retreat
July 26, 7:45a | Corporate College East
Cancer Center members, fellows, post-docs and trainees will come together tomorrow at Corporate College East for the remainder of the Annual Scientific Retreat.

Breakfast and registration will open at 7:45 am with Director Stan Gerson, MD starting the day with a presentation on strategic direction at 8:10, followed by trainee platform presentations, then our Keynote presentation from Anil Rustgi, MD at 9 am. Dr. Rustgi
is a  leading cancer researcher of gastrointestinal tumors and  Director of the Herbert Irving Comprehensive Cancer Center at  Columbia University Irving Medical Center. He will present, "P120catenin, EMT-MET plasticity and metastatic pancreatic cancer."

The rest of the day is filled with scientific presentations and breakouts for each of our research programs. Late registration for retreat is available day-of.  More details are available in the  full retreat agenda>
A MESSAGE FROM...
Erika Trapl, PhD
Co-Leader, Cancer Prevention, Control, & Population Research Program, Case Comprehensive Cancer Center
Associate Director, Prevention Research Center for Healthy Neighborhoods, CWRU
Associate Professor,  Population and Quantitative Health Sciences
Ohio's New "Tobacco 21" Law: A Step in the Right Direction
Beginning October 17, 2019, selling any tobacco or vapor product to anyone under the age of 21 will become illegal in the state of Ohio. Legislation adopting what is commonly known as "Tobacco 21" was signed into state law by Governor Mike DeWine on July 18 as part of the 2020-2021 biennial operating budget. The City of Cleveland was the first major city in Ohio to adopt Tobacco 21 in December 2015. Prior to the state's passage of Tobacco 21, seven additional municipalities in Cuyahoga County had adopted legislation to increase the legal tobacco purchase age to 21.
 
Tobacco 21 policy has been proposed as one policy approach to reduce youth tobacco use. While cigarette use has been declining, use of non-cigarette products, such as electronic cigarettes, has continued to attract youth. The premise behind Tobacco 21 policy is that by increasing the legal purchase age, the number of near-age peers who are legally able to purchase tobacco products is significantly reduced, ultimately reducing youth access to tobacco and nicotine products and subsequent nicotine dependence. Given the overwhelming proportion of current adult smokers who began smoking during adolescence, this policy has implications for longer-term adult smoking rates.
 
Passing legislation is just the first step; state agencies will now be tasked with implementing the new state law. As part of the budget bill, the role of the Tobacco Control Program at the Ohio Department of Health was expanded such that that agency can use funds to "administer compliance checks, retailer education, and programs related to legal age restrictions." This language recognizes that state agencies must have resources to build out strong implementation and enforcement actions to maximize the impact of the policy. Tobacco control advocates, including the American Cancer Society, had expressed concerns about the weak enforcement language included in this legislation and will likely be paying close attention to the retailer compliance and enforcement.
 
Importantly, the Ohio legislation does not include criminal penalties for youth who purchase, use, or possess these products, which follows model policy language advocated by the tobacco control community. The budget bill does include a new tax on vapor products at $0.10/ml and requires licensure of all retailers selling tobacco or vapor products.
 
Here in Cleveland, Tobacco 21 went into effect in April 2016. Local data collected by the Prevention Research Center for Healthy Neighborhoods (PRCHN) at Case Western Reserve University in 2015 and 2017 demonstrated a significant decline in the proportion of high school youth who were currently using cigarettes and cigar products following implementation of Tobacco 21. However, compliance checks conducted by the PRCHN indicate that just over half of sampled tobacco retailers sold cigarettes or cigarillos to individuals under 21. This is likely due to the limited resources invested in enforcement, and this is an area that the Cleveland Department of Public Health is currently working to address.
 
There is no silver bullet to preventing youth tobacco use, but the adoption of Tobacco 21 by the state of Ohio is a step in the right direction to curbing nicotine dependence and the myriad tobacco-related diseases experienced by Ohio residents.
MEMBER/CENTER HIGHLIGHTS
New, High-Resolution Images Reveal Clues to Improve Anti-Nausea Drugs for Cancer Patients
A new study using a special type of electron microscope using samples cooled to extremely cold temperatures provides critical information for drug developers seeking to reduce nausea and vomiting side effects of cancer treatments. Published in Nature Communications, the study offers a glimpse into how widely-used anti-nausea drugs attach to their target protein in the gastrointestinal tract. High-resolution images obtained by this method provide key details about how the drugs attach into a binding pocket on the protein-and offer clues into how their design might be improved.
 
The study focused on a specific class of drugs used to manage nausea, vomiting, and irritable bowel syndrome, called setrons. Setrons are generally well-tolerated, but some cancer patients do not respond to them, explained study lead Sudha Chakrapani, PhD, associate professor of physiology and biophysics at Case Western Reserve University School of Medicine.
 
"Cancer patients who have vomiting later in their treatment plans-delayed emesis-don't tend to respond to setrons," Chakrapani said. "There is a constant need for better drugs." Drug improvement has been stalled by a lack of models showing exactly how drugs like setrons attach to their target protein in the body-the serotonin (3) receptor. Without a precise model, drug developers have been unable to understand exactly which elements of setron-receptor interactions are most important, and how to enhance them. more>
Team Case CCC Beat the Heat in VeloSano 6
They say that there's strength in numbers and that was certainly the case as brightly colored jerseys were spotted at every turn throughout the past weekend at VeloSano's 6th signature "Bike To Cure" event. By kick-off, a total of 92 individuals had joined Team Case Comprehensive Cancer Center to ride in-person or virtually, committing to raise funds for cancer research right here in Cleveland through pilot funding at Cleveland Clinic and the Case CCC. View VeloSano 5 awardees>

Over the weekend, Team Case CCC riders covered more than 4,820 miles on various routes ranging from 10 to nearly 200 miles in length. Including virtual riders, the team has currently raised over $57,354 in online donations.


Thank you to all those who rode with us, volunteered for our cheer station, or supported our team through donations! The funds raised go directly to cancer research thanks to VeloSano's incredible partners. The team is able to continue to collect tax-deductible contributions through October 1, 2019 if you would like to show your support!

Check out our growing gallery of photos from the weekend and if you're willing to share any pictures you took over the weekend, please send them to cancer@case.edu!
Deadline Approaching for Fall Admission for Two-Year Master's Level Program in Regenerative Medicine and Entrepreneurship 
The RGME is the first two-year master's level program in Ohio focused on Regenerative Medicine and Entrepreneurship. 

Students enrolled in the RGME program will have access to cutting-edge clinical and research facilities along with small biotechnology companies within the network of the National Center for Regenerative Medicine (NCRM).

This unique, interdisciplinary program will provide a rigorous educational pathway targeting individuals seeking the advanced skills and training required to excel in the unique workforce necessary to support the exponential growth and application of the field of regenerative medicine. The Master's program in RGME will train individuals to work in academic, commercial, and clinical settings to support cellular manufacturing, biotechnology innovation, legal and compliance, financial analyst and venture capital, and business development activities taking advantage of our strengths across the disciplines of regenerative medicine as a whole.  Submit applications by August 1, 2019 for consideration for the Fall 2019 term. Learn more>
MARK YOUR CALENDARS
Cancer-focused Summer Undergraduate Research (CanSUR) Symposium
August 7, 9a-12p | WRB Auditorium

The CanSUR Program Symposium will be held Wednesday, August 7 from 9 am to 12 pm in the Wolstein Research Building auditorium. Please join us as our 32 CanSUR scholars present their research as short, 3-minute "elevator pitch" presentations.

Following the presentations, a luncheon will be held as we close out the first year of our program. If you would like to attend the luncheon, please RSVP to Gena Richmann ( gnb15@case.edu).
Registration Now Open: Artificial Intelligence in Oncology Symposium
Oct 24, 2019 | Tinkham Veale University Center

On October 24, the Case Comprehensive Cancer Center will host the inaugural Artificial Intelligence in Oncology Symposium: Advancements in Policy at Case Western Reserve University.

The symposium will bring together experts in AI and machine learning  as well as clinical, industry and federal agency experts in pathology, radiology, oncology and immuno-oncology to speak on research developments, regulatory policy, reimbursement and ethics surrounding AI.

Symposium Highlights:
  • Focused panel discussions
  • Networking opportunities
  • Exhibitions available throughout the day
Be sure to register by August 30, 2019 to secure our discounted early bird registration. A discounts for students and trainees who wish to attend is available. We look forward to seeing you in October!  Save your seat>
Innovators in AYA Cancer: Driving Science and Policy toward a Brighter Future for Teens and Young Adults with Cancer
Nov 14-15, 2019 | Tinkham Veale University Center
Registration will be opening soon for the Case Comprehensive Cancer Center's AYA Oncology Symposium taking place November 14-15, 2019 at Tinkham Veale University Center at Case Western Reserve University! Sign up to receive updates>
FEATURED PROFILE: STAFF
Kevin C. Hoy, PhD, Director, Clinical Research Office
This past May, the Case Comprehensive Cancer Center welcomed Kevin Hoy, PhD as Director of the Clinical Research Office.

In his role at the Cancer Center, he oversees compliance with the Cancer Center Support Grant FOA section on clinical research, developing strategies and policies to support coordinated clinical trial activity across the consortium institutions (University Hospitals and Cleveland Clinic) and manages the Protocol Review and Monitoring Committee; including clinical trial audits and federal reporting.

Kevin obtained his PhD from Texas A&M University in Behavioral Neuroscience. Kevin's graduate research focused on the intrinsic mechanisms of the spinal cord to recover lower limb locomotion after traumatic injury. As a post-doctoral fellow, Kevin examined the physiological mechanisms of breathing recovery after cervical spinal cord injury. Prior to joining the Comprehensive Cancer Center, Kevin worked as an Institutional Review Board Specialist at The MetroHealth System.

Kevin's office is located in the cancer center's main administration suite, 1-422B, straight in the door and to the left. Be sure to introduce yourself next time you're in the suite!
FUNDING OPPORTUNITIES
Oncology Nursing Foundation Research Grant
LOI Deadline: Aug 15, 2019

The Oncology Nursing Foundation is accepting letters of intent for 2-year research grants of up to $25,000.  These grants support oncology nursing research. Research projects may include pilot or feasibility studies or the development of a new aspect of a program of research. Funding preference is given to research that addresses the ONS Research Priorities and/or the ONS Research Agenda. 

The principal investigator must be actively involved in some aspect of cancer patient care, education, or research, and be PhD- or DNSc-prepared. Funding preference is given to projects that involve nurses in the design and conduct of the research activity and that promote theoretically based oncology practice. Membership in ONS is not required for eligibility. more>
IN THE NEWS
Phys.org - July 15, 2019
"We think we can begin to see those changes within a week, as compared to six months," said Mark Griswold, PhD, CWRU professor of radiology, director of MRI research and Case CCC member.

Doctors using electricity to control brain tumor cells
A BC 6 - July 22, 2019
" It disrupts cells that are trying to divide and since it is cancer cells that are actually the ones dividing, those get killed preferentially," says Cleveland Clinic's David Peereboom, MD, member of the Case CCC's Developmental Therapeutics Program.
NIH BULLETIN - Notices and Funding Opportunities
Notices
Extension of Certain Flexibilities for Prospective Basic Experimental Studies With Human Participants

Registration Open for the ICARE Academy on September 10-11, 2019, in Alexandria, VA

Notice of Clarification to PAR-18-841, "Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)"

Funding Opportunities
Deadline: October 22, 2019

Deadline:  October 22, 2019


Deadline: November 1, 2019

Deadline: November 22, 2019
IN THIS ISSUE
EVENTSevents
Thurs, July 25
Case CCC Annual Scientific Retreat
Details
2:30p Tinkham Veale University Center

Case CCC TED Talks
Details
5-6p Tinkham Veale University Center
Fri, July 26
Case CCC Annual Scientific Retreat
Details
7:45a Corporate College East
Thurs, Aug 1
Developmental Therapeutics Journal Club
9a NE6-218

Molecular Biology and Microbiology Virology Journal Club
1p SOM W203
Sun, Aug 4
Miles for Melanoma 5K Run/Walk
7:30a Edgewater Park
Mon, Aug 5
6th Annual Data Science in Life Science and Engineering Symposium
9a Tinkham Veale University Center
Tues, Aug 6
6th Annual Data Science in Life Science and Engineering Symposium
Details
9a Tinkham Veale University Center
Thurs, Aug 8
Developmental Therapeutics Journal Club
9a NE6-218

Molecular Biology and Microbiology Virology Journal Club
1p SOM W203
Fri, Aug 9
UH Seidman Cancer Center Grand Rounds
8a Wearn 137
Sat, Aug 10
Susan G. Komen Cleveland "More Than Pink" Walk
Details
9:45a Wade Oval
ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
prev-funding
PREVIOUSLY ANNOUNCED OPPORTUNITIES

Deadline: Open

Deadline: Open

Deadline: Open
Case Comprehensive Cancer Center